The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
09/05/2012 08:40:01 NGG 89.00 O 1,327 GLA
08/05/2012 15:42:10 NGG 89.00 O 661 GLA
A good volume at the close. 21/10/2011 16:40:37 BIOM 0.19 UT 850,000 **** UT 21/10/2011 15:53:14 BIOM 0.19 O 1,000,000 21/10/2011 15:50:54 BIOM 0.19 O 7,000,000 21/10/2011 15:47:36 BIOM 0.19 AT 1,000,000 21/10/2011 15:46:57 BIOM 0.19 AT 500,000 21/10/2011 15:46:53 BIOM 0.19 AT 1,000,000 21/10/2011 15:46:53 BIOM 0.19 AT 500,000 21/10/2011 15:38:47 BIOM 0.18 O 3,010,000 21/10/2011 15:38:35 BIOM 0.18 O 50,000 21/10/2011 15:08:12 BIOM 0.18 O 500,000 gla
A few of ours are looking good this morning ... VAL, PYC. ect ATB Mark
extGen Group PLC Launch of new multiplex protein plasma assay RNS Number : 7698E NextGen Group PLC 13 April 2011 NextGen Sciences NextGen Sciences launches multiplex protein plasma biomarker assay for breast cancer Ann Arbor, Michigan, US, and London, UK, 13 April 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmabreast25 multiplex protein assay, targeting breast cancer biomarker discovery and qualification. The assay simultaneously measures 25 human plasma proteins that are thought to have potential as biomarkers in breast cancer. Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of plasmabreast25 is further indication of our commitment to developing and marketing multiplex assays for biomarker discovery in specific cancer areas. It enables us to remain focused on increasing our market share from the $600m mass spectrometry based biomarker discovery market. To ensure we continually deliver the high-quality assays that pharmaceutical, biotechnology and diagnostics companies need to inform their decision-making processes, NextGen Sciences is currently planning more such products in the near future.' GLA NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to develop further oncology and CNS disease-focused assay panels, both as proprietary products and with other companies, through partnerships and collaborations. - ENDS - For more information please contact : NextGen Group Klaus Rosenau, Chairman and CEO klaus.rosenau@nextgensciences.com +49 160 551 6756 Seymour Pierce Jonathan Wright, Nicola Marrin +44 (0) 20 7107 8000
Is there any reason for the recent rise in the SP. thanks GLA
Hi larney Bought in again this morning. This is a very good company with a strong and loyal workforce, a great management team and has a good history of dividend. It is the largest manufacturer in Europe and a good global perspective, it also addresses lots of green issues, being involved in and investing in recycling. I must state that I know the MD and his family and have done for 40 years. The MD is a man of supreme integrity and I believe that he buys this share when it's up and when it's down, so please do not rely on director's buys as an indicator. DYOR BPI has moved up and down on small volume and I believe that it under priced at the moment. BW to all
Hi Welcome back ATB Mark
Well! What a good start. I believe this will rise all day and perhaps very quickly after the budget. GLA
Kitchens and all I don't know if we will have a big movement today ... GLA
AYE
LMFAO
If you own 1 mil+ then you become a super turd.......... GL